References
- Banales JM, Cardinale V, Carpino G, et al. Expert consensus document: cholangiocarcinoma: current knowledge and future perspectives consensus statement from the European Network for the Study of Cholangiocarcinoma (ENS-CCA). Nat Rev Gastroenterol Hepatol. 2016;13(5):261‐280.
- Amin MB, Edge S, Greene F, et al. AJCCCancer staging manual. 8th ed. Chicago (IL): American College of Surgeons; 2017.
- Lee AJ, Chun YS. Intrahepatic cholangiocarcinoma: the AJCC/UICC 8th edition updates. Chin Clin Oncol. 2018;7(5):52.
- Bridgewater J, Galle PR, Khan SA, et al. Guidelines for the diagnosis and management of intrahepatic cholangiocarcinoma. J Hepatol. 2014;60(6):1268‐1289.
- Buettner S, van Vugt JL, Ijzermans JN, et al. Intrahepatic cholangiocarcinoma: current perspectives. Oncol Targets Ther. 2017;10:1131–1142.
- Doherty B, Nambudiri VE, Palmer WC. Update on the diagnosis and treatment of cholangiocarcinoma. Curr Gastroenterol Rep. 2017;19(1):2.
- Adeva J, Sangro B, Salati M, et al. Medical treatment for cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):123‐142.
- Khan SA, Tavolari S, Cholangiocarcinoma BG. Epidemiology and risk factors. Liver Int. 2019;39(Suppl 1):19‐31.
- Bertuccio P, Malvezzi M, Carioli G, et al. Global trends in mortality from intrahepatic and extrahepatic cholangiocarcinoma. J Hepatol. 2019;71(1):104‐114.
- Bergquist A, von Seth E. Epidemiology of cholangiocarcinoma. Best Pract Res Clin Gastroenterol. 2015;29(2):221‐232.
- Katkade VB, Sanders KN, Zou KH. Real world data: an opportunity to supplement existing evidence for the use of long-established medicines in health care decision making. J Multidiscip Healthc. 2018 Jul 2;11:295–304.
- Justo N, Espinoza MA, Ratto B, et al. Real-world evidence in healthcare decision making: global trends and case studies from Latin America. Value Health. 2019 Jun;22(6):739–749.
- Centers for Disease Control and Prevention (CDC). International classification of diseases, ninth revision, clinical modification (ICD-9-CM). CDC; 2015. [cited 2020 Jun 26]. Available from: https://www.cdc.gov/nchs/icd/icd9cm.htm.
- Centers for Disease Control and Prevention (CDC). International classification of diseases, tenth revision, clinical modification (ICD-10-CM). CDC; 2020. [cited 2020 Jun 26]. Available from: https://www.cdc.gov/nchs/icd/icd10cm.htm.
- Law 14/2007, of July 3, on biomedical research (BOE, 4 July 2007). Rev Derecho Genoma Hum. 2007 Jan-Jun; 26:283–325.
- Organic Law 3/2018, of December 5, on data protection and guarantee of digital rights. Official State Gazette [Boletín Oficial del Estado]. 2018 Dec; 294:119788–119857.
- Ministry of Health, Consumer Affairs and Social Welfare. Health care information and statistics. Ministry of health, consumer affairs and social welfare; 2019. [cited 2020 Jun 26]. Available from: https://www.mscbs.gob.es/estadEstudios/sanidadDatos/home.htm.
- Fernández-Ruiz M, Guerra-Vales JM, Colina-Ruizdelgado F. Comorbidity negatively influences prognosis in patients with extrahepatic cholangiocarcinoma. World J Gastroenterol. 2009;15(42):5279‐5286.
- Bertuccio P, Bosetti C, Levi F, et al. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013;24(6):1667‐1674.
- Massarweh NN, El-Serag HB. Epidemiology of hepatocellular carcinoma and intrahepatic cholangiocarcinoma. Cancer Control. 2017;24(3):1073274817729245.
- Saha SK, Zhu AX, Fuchs CS, et al. Forty-year trends in cholangiocarcinoma incidence in the U.S.: intrahepatic disease on the rise. Oncologist. 2016;21(5):594‐599.
- Zhang H, Yang T, Wu M, et al. Intrahepatic cholangiocarcinoma: epidemiology, risk factors, diagnosis and surgical management. Cancer Lett. 2016;379(2):198‐205.
- Forner A, Vidili G, Rengo M, et al. Clinical presentation, diagnosis and staging of cholangiocarcinoma. Liver Int. 2019;39(Suppl 1):98‐107.
- Huguet JM, Lobo M, Labrador JM, et al. Diagnostic-therapeutic management of bile duct cancer. World J Clin Cases. 2019;7(14):1732‐1752.
- Sangchan A, Chaiyakunapruk N, Supakankunti S, et al. Cost utility analysis of endoscopic biliary stent in unresectable hilar cholangiocarcinoma: decision analytic modeling approach. Hepatogastroenterology. 2014;61(133):1175–1181.
- Cillo U, Spolverato G, Vitale A, et al. Liver resection for advanced intrahepatic cholangiocarcinoma: a cost-utility analysis. World J Surg. 2015;39(10):2500–2509.
- Ghodadra A, Xing M, Zhang D, et al. Yttrium-90 radioembolization is cost effective in intrahepatic cholangiocarcinoma: a SEER medicare population study. J Vasc Interv Radiol. 2019;30(3):293–297.
- Spanish Ministry of Health. Weights of the GRDs of the national health system. Spanish ministry of health; 2019. [cited 2020 Sep 29]. Available from: https://www.mscbs.gob.es/en/estadEstudios/estadisticas/inforRecopilaciones/anaDesarrolloGDRanteriores.htm.